Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 18, 2011 Helen Bache	Sugar injection to beat hospital infection A carbohydrate from the surface of the most virulent strain of the bacterium Clostridium difficile has been synthesised by chemists in Germany. The molecule could be used to develop a vaccine against the infection.
Chemistry World March 23, 2009 Nina Notman	First auto carbohydrate synthesiser German researchers have unveiled the first fully automated carbohydrate synthesizer, which they hope will advance development of carbohydrate-based vaccines for the developing world.
Chemistry World September 2, 2007 Simon Hadlington	Sweet Approach to Tackling Cancer A promising new 'slimline' cancer vaccine that triggers a powerful immune response against excessive sugar molecules has been unveiled by researchers.
Chemistry World March 3, 2009 Lewis Brindley	Sweet-toothed bacteria make their own vaccine With careful feeding, bacteria can produce vaccines against themselves, scientists in the US and China have found.
Chemistry World February 5, 2014 Jenifer Mizen	Protein-free and low sugar -- not a new diet, a new vaccine A Streptococcus pneumonia vaccine with fewer sugar units and no antigenic protein is not only easier to produce but could also induce a superior immune response to the vaccine currently in clinical use.
Chemistry World January 17, 2010 Simon Hadlington	Sugars synthesised with help of promiscuous enzyme European researchers have discovered a new way to make synthetically elusive sugar molecules that could lead to novel vaccine candidates and other medically important compounds.
Chemistry World July 1, 2013 James Urquhart	Antibiotic research hits a sweet spot UK researchers have found a way to weaken the molecular armour of Escherichia coli to allow the host's immune system to attack and kill the pathogen.
Chemistry World January 20, 2014 Martha Henriques	Fast test classifies meningitis bacteria Researchers in the UK have developed a new method that uses surface enhanced Raman scattering to quickly identify which meningitis causing bacteria is responsible for an infection.
Nurse Practitioner July 2011 Lori Mertz	Meningococcal Disease: Early Recognition is Vital to Patient Outcomes Education of healthcare professionals to improve identification and provide immediate treatment of patients with symptoms consistent with meningococcal disease will result in improved outcomes.
American Family Physician November 15, 2005 Sanford R. Kimmel	Prevention of Meningococcal Disease Invasive disease caused by Neisseria meningitidis has an average annual incidence of one case per 100,000 in the United States. The disease can be rapidly fatal or result in severe neurologic and vascular sequelae despite antibiotic therapy.
The Motley Fool May 22, 2007 Mike Havrilla	An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note.
Chemistry World March 30, 2012 Laura Howes	Printing vaccines for the masses with nano-fabrication Applying nanoparticle fabrication techniques to vaccine production could dramatically cut their cost per dose.
Bio-IT World June 15, 2003 Malorye Branca	A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery?
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources.
Reactive Reports Issue 58	Anthrax Detector Researchers have developed a detector for anthrax spores based on a monoclonal antibody that recognizes a specific sugar on the bacterium. It might be possible to use this discovery to develop a passive immunization method.
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
The Motley Fool September 19, 2007 Billy Fisher	Prevnar Problems at Wyeth? New strains of bacteria might make the popular pneumonia vaccine less effective. While Prevnar might come under siege from superbugs, one doubts that Wyeth's stock price will become similarly cure-resistant.
Nursing November 2007 Matthews, Miller & Mott	Getting Ahead of Acute Meningitis & Encephalitis Learn how to distinguish between these common central nervous system infections and respond appropriately.
Chemistry World July 29, 2015 Maria Burke	Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear.
Chemistry World January 20, 2012 Andy Extance	Tube-wrapped lamp makes malaria drug German researchers have developed an inexpensive three-step continuous flow synthesis of artemisinin, the key drug in the ongoing fight against malaria.
American Family Physician May 15, 2001	Pneumococcal Conjugate Vaccine: What a Parent Needs to Know Why should my child get this vaccine?... What exactly is the pneumococcal vaccine?... Are there some children who should not get pneumococcal conjugate vaccine or who should wait until they are older?...
Wired September 2002 Amanda Griscom	Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
Chemistry World April 2007 Derek Lowe	Opinion: In the Pipeline Natural products can be ridiculously complicated. The sheer difficulty of the enterprise is traditionally what made pharmaceutical companies hire people who had worked in total synthesis. But, is total synthesis research still worth the effort?
Chemistry World September 10, 2014 Elisabeth Ratcliffe	Antimalarial flow synthesis closer to commercialization Scientists in Germany have demonstrated the large scale and inexpensive production of a range of antimalarial drugs, using a continuous flow system.
HHMI Bulletin Feb 2012 Nancy Ross-Flanigan	A Safer Shot at TB While trying to understand tuberculosis bacteria genes, researchers discovered a safe way to shut down the bacteria.
Chemistry World September 26, 2007 Victoria Gill	HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed.
American Family Physician July 15, 2003 Sur et al.	Vaccinations in Pregnancy Routine vaccines that generally are safe to administer during pregnancy include diphtheria, tetanus, influenza, and hepatitis B. Other vaccines, such as meningococcal and rabies, may be considered.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
American Family Physician July 1, 2004	Travel Vaccines An informative brochure on the importance of travel vaccines and procedures regarding their use.
AskMen.com	Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
BusinessWeek April 26, 2004 Kerry Capell	Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
BusinessWeek April 30, 2007 Catherine Arnst	Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
Chemistry World February 7, 2006 Jon Evans	Plant-Derived Drug Approved in US Dow AgroSciences has become the first biotech firm to gain US regulatory approval for a plant-derived drug. The company claims it will be able to manufacture many other vaccines, for animal and human diseases, using its plant-based production technology.
American Family Physician July 1, 2004 Lo Re & Gluckman	Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases.
Bio-IT World Jul/Aug 2006 Robert M. Frederickson	Tests for Hospital-Acquired Infections Tests for pathogens increasingly rely on genomic methods that identify specific genetic signatures of bacteria or viruses. Rapid detection of other pathogens also provides the potential for significant impact on the healthcare industry.
Scientific American April 10, 2006 Christine Soares	Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines.
Pharmaceutical Executive June 1, 2005 Seth Berkley	Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
Pharmaceutical Executive July 10, 2014 Fitzpatrick & Mohan	Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.
American Family Physician November 15, 2006 Stephen J. Ritz	STEPS Tetravalent meningococcal conjugate vaccine (Menactra) for the prevention of meningococcal disease.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
Chemistry World January 19, 2015 Maria Burke	Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine.
AskMen.com Jacob Franek	2008 Medical Science Developments Here are some 2008 medical science developments that might just yield the next big breakthrough.
Chemistry World August 30, 2009 Phillip Broadwith	C-H oxidation proves its worth US researchers are going against the grain of total synthesis and developing new approaches to complex molecules.